| |
|
|
|
|
|
|
|
Trends in Medicinal Chemistry
6th December 2018
Friends House, Euston Road, London
|
|
Programme |
|
|
|
|
08.30
|
Registration and coffee |
|
|
|
|
09.25 |
Welcome and introduction - David Pryde, Curadev Pharma Ltd |
|
|
|
Session 1: Finding and Modulating New Targets
Chair: David Pryde, Curadev Pharma Ltd |
|
09.30 |
Mike Hann, GSK, UK
‘PhABits – shining new light on fragment approaches' |
|
|
|
|
10.10 |
Christian Ottmann, Technische Universiteit Eindhoven, NL
‘Stabilization of PPIs in drug discovery' |
|
|
|
|
10.50 |
Coffee break |
|
|
|
Session 2: Enabling Computational Technologies
Chair: Mo Alavijeh, Pharmidex Pharmaceutical Services Ltd. |
|
11.10 |
Quentin Perron, IKTOS, FR
‘AI approaches to drug design' |
|
|
|
|
11.50 |
Peter Coveney, UCL, UK
‘Predicting ligand-protein binding affinities - rapidly, accurately and reliably' |
|
|
|
|
12.30 |
Lunch, to include the SMR AGM at 13.15 for SMR members |
|
|
|
Session 3: New modalities and delivering them
Chair: Mo Alavijeh, Pharmidex Pharmaceutical Services Ltd. |
|
13.30 |
Steve Hood, GSK, UK + Peter Watson, University of Cardiff, UK
‘Public Private Partnerships - what’s in it for industry, academia and patients?' |
|
|
|
|
14.10 |
Garrick Smith, Nuevolution, DK
‘Development of small molecule inhibitors of IL17A/IL17RA identified from DNA Encoded Libraries' |
|
|
|
|
14.50 |
Coffee break |
|
|
|
Session 4: Peptide Drug Discovery
Chair: Mike Hann, GSK |
|
15.10 |
Thomas Vorherr, Novartis, CH
‘Discovering peptide drugs' |
|
|
|
|
15.50 |
Laurent Knerr, AZ, SE
‘Design and application of novel peptide conjugates for targeted delivery approaches' |
|
|
|
|
16.30 |
Closing comments and end of meeting - Mike Hann, GSK |
|
|
|
|
|
|
Back to Menu |
Sponsored by
| |
